Journal article
Investigational Drugs Targeting HDL-C Metabolism And Reverse Cholesterol Transport
Future lipidology, Vol.2(3), pp.285-301
06/01/2007
DOI: 10.2217/17460875.2.3.285
Abstract
Low high-density lipoprotein cholesterol (HDL-C) levels are associated with higher risk of cardiovascular disease, even in patients receiving statin therapy. HDL-C has a number of potential atheroprotective mechanisms, including reverse cholesterol transport. HDL-C also has antioxidant, anti-inflammatory, vasodilatory and antithrombotic effects. A number of targets with the potential to raise HDL-C levels and/or increase reverse cholesterol transport have been identified. Plasma concentrations of HDL-C are the net result of the de novo production, catabolism and recycling of HDL-C particles, as well as the contribution to HDL-C from components of other lipoproteins. HDL-C levels can be modified by increasing the production of apolipoprotein A-I or by delaying the clearance of HDL-C from the plasma. Whether manipulation of these drug targets to raise HDL-C will result in cardiovascular event reduction remains to be determined.
Details
- Title: Subtitle
- Investigational Drugs Targeting HDL-C Metabolism And Reverse Cholesterol Transport
- Creators
- Jennifer G. Robinson - University of Illinois Urbana-ChampaignMichael H. Davidson - University of Illinois College of Medicine Peoria, IL, USA
- Resource Type
- Journal article
- Publication Details
- Future lipidology, Vol.2(3), pp.285-301
- Publisher
- Taylor & Francis
- DOI
- 10.2217/17460875.2.3.285
- ISSN
- 1746-0875
- Language
- English
- Date published
- 06/01/2007
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984364456902771
Metrics
9 Record Views